MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
- John F. Seymour
- , Thomas J. Kipps
- , Barbara Eichhorst
- , Peter Hillmen
- , James D'Rozario
- , Sarit Assouline
- , Carolyn Owen
- , Tadeusz Robak
- , Javier de la Serna
- , Ulrich Jaeger
- , Guillaume Cartron
- , Marco Montillo
- , Nicole Lamanna
- , Maria E. Verdugo
- , Elizabeth Punnoose
- , Yanwen Jiang
- , Jue Wang
- , Michelle Boyer
- , Kathryn Humphrey
- , Mehrdad Mobasher
Research output: Contribution to journal › Meeting Abstract › peer-review